[Sponsored Report] Suspen now provides cold relief day and night

Home > National > Guest Reports

print dictionary print

[Sponsored Report] Suspen now provides cold relief day and night

테스트

Hanmi Pharm’s Suspen cold medicine now comes in day and nighttime dosages. [HANMI PHARM]

Hanmi Pharm has re-released its cold medicine, Suspen, which is now categorized into day and nighttime dosages depending on when it is taken.

Both products are effective for a wide range of cold symptoms, including fever, nasal congestion, sore throat and cough.

Suspen Day tablets contain the fever-reducing substance acetaminophen; chlorpheniramine, which suppresses allergic reactions; and pseudoephedrine, which is effective on sinus colds.

Nighttime tablets contain phenylephrine, which soothes allergic reactions and induces sleep; it was included to guarantee deep sleep for patients with the flu in order to speed up their recovery time.

Both products are distinguishable not only in their packaging but in the tablet itself, designed to prevent patients from taking the wrong dose.

Suspen Day tablets are white in color, while the Night tablets are blue. The time of the dose is also engraved on each respective pill.

Suspen Day and Night tablets are appropriate for adults and teenagers over the age of 12.

The recommended dosage is one to two pills every four to six hours. Both products will be distributed in pharmacies nationwide by Hanmi’s affiliate marketing company Online-Pharm.

“The intent of Suspen’s re-release was to offer a product that differs according to the customer’s symptoms and situation,” a Hanmi Pharm spokesman said.


BY SONG KYOUNG-SON [song.kyoungson@joongang.co.kr]

More in Guest Reports

Hyundai E&C’s Daegu complex boasts convenience

[SPONSORED REPORT] Hyundai Mobis strengthens its global R&D network

[SPONSORED REPORT] Posco practices its own motto by giving back

[SPONSORED REPORT] Chong Kun Dang offers solution for parasitic worms

[SPONSORED REPORT] Kumho Tire successfully streamlines operations

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now